zedoresertib (Debio 0123)

About Debiopharm

Debiopharm is a 45-year-old, privately held biopharmaceutical company based in Lausanne, Switzerland, employing approximately 420 people. It operates a hybrid business model combining proprietary drug development in oncology and infectious diseases with contract manufacturing and venture investment in digital health. The company's pipeline features a range of novel modalities, including antibody-drug conjugates (ADCs), small molecule inhibitors, and peptides, targeting various hallmarks of cancer. With a history of successful drug launches and a focus on enabling future standards of care, Debiopharm positions itself as a specialized developer and strategic partner in the life sciences ecosystem.

Therapeutic Areas

Other Oncology (Genome Instability) Drugs